Single B-cell deconvolution of peanut-specific antibody responses in allergic patients - 07/01/16

Abstract |
Background |
The frequencies, cellular phenotypes, epitope specificity, and clonal diversity of allergen-specific B cells in patients with food allergy are not fully understood but are of major pathogenic and therapeutic significance.
Objective |
We sought to characterize peanut allergen–specific B-cell populations and the sequences and binding activities of their antibodies before and during immunotherapy.
Methods |
B cells binding fluorescently labeled Ara h 1 or Ara h 2 were phenotyped and isolated by means of flow cytometric sorting from 18 patients at baseline and 13 patients during therapy. Fifty-seven mAbs derived from allergen-binding single B cells were evaluated by using ELISA, Western blotting, and peptide epitope mapping. Deep sequencing of the B-cell repertoires identified additional members of the allergen-specific B-cell clones.
Results |
Median allergen-binding B-cell frequencies were 0.0097% (Ara h 1) or 0.029% (Ara h 2) of B cells in baseline blood from allergic patients and approximately 3-fold higher during immunotherapy. Five of 57 allergen-specific cells belonged to clones containing IgE-expressing members. Almost all allergen-specific antibodies were mutated, and binding to both conformational and linear allergen epitopes was detected. Increasing somatic mutation of IgG4 members of a clone was seen in immunotherapy, whereas IgE mutation levels in the clone did not increase.
Conclusion |
Most peanut allergen–binding B cells isolated by means of antigen-specific flow sorting express mutated and isotype-switched antibodies. Immunotherapy increases their frequency in the blood, and even narrowly defined allergen epitopes are recognized by numerous distinct B-cell clones in a patient. The results also suggest that oral immunotherapy can stimulate somatic mutation of allergen-specific IgG4.
Le texte complet de cet article est disponible en PDF.Key words : Peanut, allergy, B cell, antibody, IgE, IgG4, immunotherapy, high-throughput DNA sequencing, antigen specific, allergen specific, repertoire, somatic mutation
Abbreviations used : CDR, IGHD, IGHJ, IGHV, OIT
Plan
| Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Disease (NIAID) grant 1U19AI0420901 and support from the Child Health Research Institute at Stanford University grant UL1 TR000093, NIH CTSA award UL1 RR025744-04 (Project 39719), NIH award R21AI09583801, the Stanford Allergy Center Fund, and the Myra Reinhard Foundation. |
|
| Disclosure of potential conflict of interest: R. A. Hoh has received research support from the Child Health Research Institute of Stanford (UL1 TR000093). S. D. Boyd has received research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, the Department of Defense, the National Institutes of Health, and the Ellison Medical Foundation; has consultant arrangements with Immumetrix; has patents through US-TPO related to DNA sequence interpretation; has stock in CareDx and Lineage Biosciences; and has received payment for lectures and travel expenses from the Clinical Immunology Society, JASON program, International Society of Laboratory Hematology, Banff International Research Station, Keystone Symposium, Cold Spring Harbor, Brigham Young University, University of Nebraska, Mexican Congress of Immunology, Hudson Alpha Institute, University of Cincinnati, Illumina, and University of Virginia. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 137 - N° 1
P. 157-167 - janvier 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
